MEDI5752 is named as a drug or biological intervention in 4 clinical trials in our USA trial register, none of which are currently recruiting. Lead sponsors include AstraZeneca (2) and MedImmune LLC (2). Registered phase: Phase 1. Conditions studied include Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced Renal Cell Carcinoma; Selected Advanced Solid Tumors.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT03530397 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (ClinicalTrials.gov ↗) Selected Advanced Solid Tumors |
Phase 1 | Active, closed |
| NCT03819465 | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Phase 1 | Active, closed |
| NCT04522323 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (ClinicalTrials.gov ↗) Advanced Renal Cell Carcinoma |
Phase 1 | Active, closed |
| NCT04612751 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Advanced or Metastatic NSCLC |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Non-Small Cell Lung Cancer (NSCLC) | 1 |
| Advanced Renal Cell Carcinoma | 1 |
| Selected Advanced Solid Tumors | 1 |
| Advanced or Metastatic NSCLC | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 2 |
| MedImmune LLC | 2 |
| Register | MEDI5752 trials |
|---|---|
| Clinical trials in USA | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MEDI5752 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MEDI5752 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.